<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The polycomb group protein enhancer of zeste homolog 2 (EZH2), which has <z:chebi fb="0" ids="15358">histone</z:chebi> methyltransferase (<z:chebi fb="1" ids="6824">HMT</z:chebi>) activity, is overexpressed in <z:mp ids='MP_0002018'>malignant tumors</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>However, the role of EZH2 in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) invasion is little known </plain></SENT>
<SENT sid="2" pm="."><plain>Here we investigated the clinical significance, biological effects and mechanisms of EZH2 signaling </plain></SENT>
<SENT sid="3" pm="."><plain>Knockdown of EZH2 significantly reduced cell invasion and secretion of matrix metalloproteinases 2/9 (MMP2/9) in in vitro studies </plain></SENT>
<SENT sid="4" pm="."><plain>Knockdown of EZH2 dramatically increased overall survival and decreased <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> of lung in in vivo studies </plain></SENT>
<SENT sid="5" pm="."><plain>Conversely, overexpression of EZH2 significantly increased lung <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> and shortened overall survival when compared with control <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>EZH2-induced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell invasion may depend on downregulation of <z:chebi fb="27" ids="27300">vitamin D</z:chebi> receptor (VDR), which is considered to be a marker of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> invasion </plain></SENT>
<SENT sid="7" pm="."><plain>EZH2 regulates the <z:chebi fb="0" ids="15358">histone</z:chebi> trimethylation of lysine27 (H3K27me3) in the VDR promoter </plain></SENT>
<SENT sid="8" pm="."><plain>Moreover, we found that STAT3 directly binds to the EZH2 promoter and regulates VDRâ€‰downregulation in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells </plain></SENT>
<SENT sid="9" pm="."><plain>Significant inverse correlations were observed between the expression of EZH2 and pSTAT3 and that of VDR in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> tissues compared with <z:mpath ids='MPATH_458'>normal</z:mpath> tissue in patients </plain></SENT>
<SENT sid="10" pm="."><plain>We show the role of EZH2 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> and identify VDR as a target gene of EZH2 </plain></SENT>
<SENT sid="11" pm="."><plain>EZH2 expression may be directly regulated by STAT3, and STAT3 may play an important role in EZH2-mediated VDR downregulation in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>This pathway may provide potential targets in aggressive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>